Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Piperazine | HCID 4837 | — |
| Reactant | HCID 58420505 | HCID 58420505 | — |
| Reactant | HCID 59687293 | HCID 59687293 | — |
| Product | HCID 59526801 | HCID 59526801 | — |
Reaction Steps
The title compound is prepared from piperazine and ethyl 1-cyclopropyl-8-(difluoromethoxy)-6,7-difluoro-2-(methylsulfonyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate using a procedure analogous to that describing the preparation of (R)-ethyl 7-(3-(2-aminopropan-2-yl)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-2-(methylsulfonyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate. (See US 2008071086, and Hashimoto, et al., 2007) 1H NMR (CDCl3): δ 0.30-0.33 (m, 1H), 0.84-0.88 (m, 1H), 0.99-1.04 (m, 1H), 1.20-1.25 (m, 1H), 1.38 (t, J=7.2 Hz, 3H), 2.95-3.21 (m, 6H), 3.44 (s, 3H), 3.51-3.58 (m, 2H), 4.13-4.18 (m, 1H), 4.36-4.48 (m, 2H), 6.54 (dd, J=76.0 Hz, 73.0 Hz, 1H), 7.72 (d, J=12.0 Hz, 1H). 19F NMR (CDCl3): δ −120.4 (s, 1F), −82.1 (s, 2F). LCMS: m/z calcd for C21H24F3N3O6S ([M]+) 503. found ([M+H]+) 504.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08173636B2 |
|---|
| Source dataset | uspto-grants-2012_05 |
|---|
| ORD ID | ord-7c851e368ced41138724251d124f70a1 |
|---|
| Source note | uspto-grants-2012_05 |
|---|